Dermoscopy is a non-invasive, in vivo technique that allows the visualization of subsurface skin structures in the epidermis, at the dermoepidermal junction, and in the upper dermis. Dermoscopy brought a new dimension in evaluating melanocytic skin neoplasms (MSN) also representing a link between clinical and pathologic examination of any MSN. However, histopathology remains the gold standard in diagnosing MSN. Dermoscopic–pathologic correlation enhances the level of quality of MSN diagnosis and increases the level of confidence of pathologists. Melanoma is one of the most genetically predisposed among all cancers in humans. The genetic landscape of melanoma has been described in the last years but is still a field in continuous evolution. Melanoma genetic markers play a role not only in melanoma susceptibility, initiation, and progression but also in prognosis and therapeutic decisions. Several studies described the dermoscopic specific criteria and predictors for melanoma and their histopathologic correlates, but only a few studies investigated the correlation among dermoscopy, pathology, and genetic of MSN. The aim of this work is to review the published data about dermoscopic features of melanoma, their histopathological correlates with regards also to genetic alterations. Particularly, this review will focus on low-CSD (cumulative sun damage) melanoma or superficial spreading melanoma, high-CSD melanoma, and nevus-associated melanoma.

In recent years, targeted (biological) therapies have become available also for primary cutaneous T-cell lymphomas (PCTCLs) including anti-CD30 (brentuximab vedotin) in mycosis fungoides, primary cutaneous anaplastic large T-cell lymphoma, lymphomatoid papulosis; anti-CCR4 (mogamulizumab) in Sezary syndrome; anti-CD123 (tagraxofusp) in blastic plasmocytoid cell neoplasm. Moreover, anti-PD1 (nivolumab), anti-PDL1 (pembrolizumab, atezolizumab), anti-CD52 (alemtuzumab), anti-KIR3DL2-CD158k (lacutamab), and anti-CD70 (cusatuzumab) have been tested or are under investigations in phase II trials. The expression of these epitopes on neoplastic cells in skin biopsies or blood samples plays a central role in the management of PCTCL patients. This narrative review aims to provide readers with an update on the latest advances in the newest therapeutic options for PCTCLs.

Citation: Massone C, Javor S, Chiodi S, Sola S. Hypomelanotyc Basomelanocytic Tumor. Dermatol Pract Concept. 2023;13(2):e2023068. DOI: https://doi.org/10.5826/dpc.1302a68 Accepted: July 14, 2023; Published: April 2023 Copyright: ©2023 Massone et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (BY-NC-4.0), https://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited. Funding: None. Competing interests: None. Authorship: All authors have contributed significantly to this publication. Corresponding author: Cesare Massone, MD, Dermatology Unit - Ospedali Galliera. Via Volta 6, 16128, Genova (IT). Phone: 0039 010 5632 4271. Email: cesare.massone@galliera.it Keywords : basal cell carcinoma, melanoma, collision tumor, basomelanocytic tumor This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Citation: Javor S, Sola S, Brunasso AMG, Bruno W, Massone C. Seven synchronous primary melanomas on the back. Dermatol Pract Concept. 2021;11(1):e2021104. DOI: https://doi.org/10.5826/dpc.1101a104 Accepted: June 18, 2020; Published: January 29, 2020 Copyright: ©2021 Javor et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License BY-NC-4.0, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original author and source are credited. Funding: None. Competing interests: The authors have no conflicts of interest to disclose. Authorship: All authors have contributed significantly to this publication. Corresponding author: Cesare Massone, MD, Dermatology Unit, Ospedali Galliera, Via Volta 6, 16128, Genova, Italy. Email: cesare.massone@galliera.it Keywords : synchronous melanomas, chronic sun exposure, BRAF, dermoscopy This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.